Education
About Us
Working with TipRanks
Follow Us
Altimmune (ALT)
NASDAQ:ALT
ALT Stock Chart & Stats
$5.10
$0.16(2.19%)
At close: 4:00 PM EST
$5.10
$0.16(2.19%)
Day’s Range― - ―
52-Week Range$2.90 - $7.73
Previous CloseN/A
Volume1.55M
Average Volume (3M)5.88M
Market Cap
$534.23M
Enterprise Value$448.91M
Total Cash (Recent Filing)$210.78M
Total Debt (Recent Filing)$15.90M
Price to Earnings (P/E)―
Beta1.65
Next Earnings
Mar 26, 2026EPS Estimate
-0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding125,231,514
10 Day Avg. Volume6,374,810
30 Day Avg. Volume5,883,546
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)4.14
Price to Sales (P/S)25596.73
P/FCF Ratio-6.41
Enterprise Value/Market Cap0.84
Enterprise Value/Revenue22.45K
Enterprise Value/Gross Profit-30.05
Enterprise Value/Ebitda-5.36
Forecast
1Y Price Target
$15.33Price Target Upside200.59% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy And TolerabilityPhase II results demonstrated consistent improvements on non-invasive liver measures and sustained weight reduction with a favorable tolerability profile, supporting a differentiated clinical benefit in metabolic dysfunction-associated steatohepatitis (MASH).
Operational And Commercial PreparednessRecent senior hires in clinical, commercial, and legal roles combined with expanded financing flexibility enhance readiness to advance into pivotal trials and prepare for potential commercialization.
Regulatory Pathway AlignmentEnd-of-Phase 2 alignment with the FDA supports a clear path toward initiating a registrational Phase 3 program and allows inclusion of an adjusted dose to potentially enhance efficacy in the pivotal trial.
Bears Say
Competitive DynamicsIntensifying competition in the MASH landscape raises the bar for commercial viability and forces the drug to demonstrate clear and durable clinical differentiation to capture market share.
Development And Market Access RisksBroad risks including clinical development setbacks, pricing and reimbursement challenges, capital market uncertainty, and potential disruptions to trials could impede progression toward approval and launch.
Endpoint And Trial Design RiskAbsence of paired liver biopsies at critical time points leaves uncertainty around efficacy assessment given the FDA's expectation for biopsy-based endpoints, which could complicate approval strategy.
Altimmune News
ALT FAQ
What was Altimmune’s price range in the past 12 months?
Altimmune lowest stock price was $2.90 and its highest was $7.73 in the past 12 months.
What is Altimmune’s market cap?
Altimmune’s market cap is $534.23M.
When is Altimmune’s upcoming earnings report date?
Altimmune’s upcoming earnings report date is Mar 26, 2026 which is in 54 days.
How were Altimmune’s earnings last quarter?
Altimmune released its earnings results on Nov 06, 2025. The company reported -$0.21 earnings per share for the quarter, beating the consensus estimate of -$0.272 by $0.062.
Is Altimmune overvalued?
According to Wall Street analysts Altimmune’s price is currently Undervalued.
Does Altimmune pay dividends?
Altimmune pays a Monthly dividend of $873 which represents an annual dividend yield of N/A. See more information on Altimmune dividends here
What is Altimmune’s EPS estimate?
Altimmune’s EPS estimate is -0.23.
How many shares outstanding does Altimmune have?
Altimmune has 125,231,514 shares outstanding.
What happened to Altimmune’s price movement after its last earnings report?
Altimmune reported an EPS of -$0.21 in its last earnings report, beating expectations of -$0.272. Following the earnings report the stock price went up 5.067%.
Which hedge fund is a major shareholder of Altimmune?
Currently, no hedge funds are holding shares in ALT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Altimmune Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.33 (200.59% Upside)
$15.33 (200.59% Upside)
Blogger Sentiment
Bullish
ALT Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 142.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $125.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.5%
Last 30 Days ▲ 7.9%
Last 30 Days ▲ 7.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-26.61%
12-Months-Change
Fundamentals
Return on Equity
-52.61%
Trailing 12-Months
Asset Growth
47.73%
Trailing 12-Months
Company Description
Altimmune
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
ALT Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a positive outlook with significant financial growth, clinical progress in key trials, and strategic leadership enhancements. However, there are challenges related to the timing of clinical operations and dependency on regulatory changes, which could impact future trial designs and approvals.View all ALT earnings summariesALT Stock 12 Month Forecast
Average Price Target
$15.33
▲(200.59% Upside)
Technical Analysis
Tvardi Therapeutics
―
Diamedica Therapeutics
―
Alpha Tau Medical Ltd
―
enGene Holdings
―
Lexeo Therapeutics, Inc.
―
Ownership Overview
0.65% Insiders
9.08% Mutual Funds
<0.01% Other Institutional Investors
77.20% Public Companies and Individual Investors